Superantigen peptide antagonists failed to block T-cell activation and cytokine production as well as toxic shock induced by staphylococcal enterotoxin B (SEB) in HLA class II transgenic mice. They also failed to inhibit the binding of SEB to HLA class II molecules as well as activation of human T lymphocytes in vitro.
Bacterial superantigens (SAg) are important clinically (10) , as well as being potential agents for bioterrorism and biological warfare (6, 9) . Since SAg-mediated immunopathology is T cell dependent, blocking the formation of SAg-major histocompatibility complex class II-T-cell receptor (TCR) complexes would be therapeutically beneficial (see reference 5 for a review). Two groups have shown that peptides derived from the conserved regions of bacterial SAg could mediate such an effect (1) (2) (3) 16) . While the validity of SAg peptide antagonists has been questioned (8, 14) , the major skepticism in these studies was the animal model used. Unlike humans, mice (as well as rabbits) are resistant to SAg-induced toxic shock even at very high doses, and pretreatment with sensitizing agents, such as D-galactosamine or bacterial lipopolysaccharides, is mandatory (10) . Therefore, a thorough evaluation of these peptide antagonists in an animal model(s) in which no such sensitizing agents are used would be critical before implementing these interventions in human patients. Since we and others have shown that HLA class II transgenic mice are ideal for recapitulating human immune responses to SAg (4, 11-13, 15, 17, 18) , we evaluated the inhibitory potential of the peptide antagonists using this transgenic-mouse model.
The following peptide antagonists were tested: (i) SEB P1 (SEB 140-151, CMYGGVTEHEGN), described by Visvanathan et al. (16) , (ii) SEB P2 (SEB 150-161, TNKKKVTA QELD), (iii) SEB P12 (SEB 150-161, YNKKKATVQELD), and (iv) SEB P12A (D-Ala-YNKKKATVQELD-D-Ala). The last three peptides are described by Arad et al. (3) . Peptides were synthesized at the Mayo Clinic Protein Core Facility. In the first set of experiments, we stimulated the splenic mononuclear cells (10 ϫ 10 6 cells/ml, 100 l/well) from HLA-DQ8 or HLA-DR3 single transgenic mice with various concentrations (100 l/well) of highly purified staphylococcal enterotoxin B (SEB), staphylococcal enterotoxin A (SEA), toxic shock syndrome toxin 1 (TSST-1), or streptococcal pyrogenic exotoxin A (SPEA) (Toxin Technologies, Sarasota, Fla.) in the presence or absence of various concentrations of the SEB antagonistic peptides (100 l/well). The cells were cultured for 48 h in tissue culture medium. Cells were pulsed with tritiated thymidine during the last 18 h of culture, and proliferation was determined by measuring the incorporated radioactivity. While SEB was capable of inducing extensive proliferation in splenocytes from HLA-DQ8 ( Fig. 1a and 2 ) and DR3 transgenic mice ( Fig. 1b and 3) , addition of the antagonistic peptides at sever- alfold-higher concentrations did not inhibit this proliferation ( Fig. 1 to 3 ), nor did they inhibit interleukin-2 production, as determined by enzyme-linked immunosorbent assay (Fig. 1c) . The antagonistic peptides SEB P12 and SEB P12A also failed to block T-cell activation by other SAg, such as SEA, SPEA, and TSST-1 ( Fig. 2 and 3 ; data with SEB P12 are not shown).
To determine the in vivo inhibitory potential of the peptide antagonists, HLA-DR3 transgenic mice were challenged with 10 g of SEB and simultaneously received a 10-fold-higher concentration of SEB P1, SEB P2, or phosphate-buffered saline (PBS). Mice were sacrificed 3 days later, and the expansion of the TCR V␤8 ϩ (SEB-reactive) CD4 ϩ and CD8 ϩ T cells was enumerated along with TCR V␤6 ϩ (SEB-nonreactive) T cells by flow cytometry. While there was a 5-to 10-fold increase in the TCR V␤8 ϩ CD4 ϩ and CD8 ϩ T cells in SEB-treated mice over the number in PBS-treated mice, coinjection of the antagonistic peptides did not block SEB-induced T-cell expansion in the spleens (Fig. 4a) . Administration of SAg also causes massive deletion of CD4-CD8 double-positive (DP) lymphocytes in the thymus (7). While there was a profound loss of CD4-CD8 DP thymocytes in mice receiving SEB alone, injection of the antagonistic peptides did not prevent this deletion on October 15, 2017 by guest http://iai.asm.org/ (Fig. 4b) . SEBP12A also failed to inhibit SEB-induced peripheral T-cell activation (Fig. 5, top) or thymocyte deletion (Fig. 5 , bottom) in vivo in DR3 mice. We have shown previously that HLA transgenic mice are highly susceptible to SAg-induced shock even without presensitization with lipopolysaccharide or D-galactosamine (11) . Two consecutive injections of 10 g of SEB at 48-h intervals induced toxic shock, which resulted in 100% mortality ( Table  1) . Coadministration of SEB antagonistic peptides (100-g doses at 0 and 48 h) at these two time points did not confer any protection from toxic shock (Table 1) , indicating the failure of SAg antagonistic peptides. We have observed that DQ8 transgenic mice with a disrupted IL-10 gene (DQ8.IL-10 Ϫ/Ϫ ) are highly sensitive to SEB-induced toxic shock (G. Rajagopalan and C. S. David, unpublished observation). While a single dose of SEB (10 g) caused 100% mortality in DQ8.IL-10 Ϫ/Ϫ mice, the peptide antagonist SEB P12A offered no protection (Table  1) . However, SEB-induced mortality in DR3 mice could be completely prevented when T-cell costimulation through CD28 was blocked by the CTLA-4Fc fusion protein (100 g; Chimerigen, Allston, Mass.) administered at the time of SEB challenge (both at 0 and 48 h) ( Table 1) .
The ability of antagonistic peptides to block SEB-induced proliferation of human peripheral blood mononuclear cells (PBMC) in vitro was also evaluated. For this, PBMC from healthy donors were obtained from a blood bank and were cultured (5 ϫ 10 6 /ml, 100 l/well) for a total of 48 h with different concentrations of SEB (100 l/well) in the presence of various concentrations of the peptide antagonists (100 l/well) in accordance with a standard protocol. Cell proliferation was determined by measuring thymidine incorporation. No inhibition in SEB-induced T-cell proliferation by the antagonists was observed (Fig. 6) . Finally, the ability of peptide antagonists to block the binding of SEB to HLA class II molecules was studied. For this human PBMC (0.5 ϫ 10 6 cells) were incubated with 10 g of biotinylated SEB (Toxin Technologies) alone or with various concentrations of SAg peptide antagonists or with nonbiotinylated SEB as competitors. After incubation and washing, cell-bound biotinylated SEB was detected by phycoerythrin-labeled streptavidin by flow cytometry. While the nonbiotinylated SEB could significantly block the binding of biotinylated SEB in a dose-dependent manner, the peptide antagonists did not show any inhibition (Fig. 7) . Incubation of the peptide antagonists with PBMC prior to addition of biotinylated SEB also did not have any inhibitory effect (data not shown). Overall, SAg peptide antagonists failed to inhibit SAg-induced T-cell activation in vitro as well as in vivo and hence warrant further evaluation before their clinical use. The applicability of HLA class II transgenic mice in such studies is underscored. a All DR3 mice received 10 g of SEB at 0 and 48 h. Where indicated, 100 g of peptides or CTLA-4Fc was injected intraperitoneally just before each injection of SEB. DQ8.IL-10 Ϫ/Ϫ mice received only one injection of SEB (10 g) and one injection of the peptide (200 g).
